Cyrtominetin is a RANKL inhibitor with favorable ADMET properties. Cyrtominetin competitively blocks the binding of RANKL-RANK and increases the compactness of RANKL . Cyrtominetin can be used in studies related to osteoporosis.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Mineral Metabolism | Products > Disease Areas > Osteoporosis | Products > Signaling Pathways > NF-κB | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > RANKL/RANK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.